Rodrigues Daniel A, Sagrillo Fernanda S, Fraga Carlos A M
Laboratório de Avaliação e Síntese de Substâncias Bioativas (LASSBio), Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, PO Box 68023, Rio de Janeiro, RJ 21941-902, Brazil.
Programa de Pós-Graduação em Química, Instituto de Química, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ 21941-909, Brazil.
Pharmaceuticals (Basel). 2019 May 6;12(2):69. doi: 10.3390/ph12020069.
Duvelisib (Copiktra) is a dual inhibitor of phosphoinositide 3-kinases (PI3Kδ and PI3Kγ). In 2018, duvelisib was first approved by the Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL) after at least two prior therapies. Duvelisib has also been approved under accelerated track for relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. In this review, we provide a series of information about duvelisib, such as the development of clinical trials for LLC/SLL and FL and the steps used for its synthesis.
度维利塞（Copiktra）是一种磷酸肌醇3-激酶（PI3Kδ和PI3Kγ）双重抑制剂。2018年，度维利塞首次获得美国食品药品监督管理局（FDA）批准，用于治疗至少接受过两种先前疗法的复发或难治性成人慢性淋巴细胞白血病（CLL）/小淋巴细胞淋巴瘤（SLL）。度维利塞也已在加速审批通道下获批，用于治疗至少接受过两种先前全身疗法的复发或难治性滤泡性淋巴瘤（FL）。在本综述中，我们提供了一系列关于度维利塞的信息，例如LLC/SLL和FL的临床试验进展及其合成步骤。
